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Objectives. This study was done to evaluate pacemaker therapy
for severe recurrent vasovagal syncope.
Background. Nonrandomized studies have suggested that per-
manent pacing might help control the symptoms of recurrent
vasovagal syncope. The study goal was to evaluate the effect of
permanent pacemaker implantation on syncope in patients with
frequently recurrent vasovagal syncope.
Methods. Patients with >26 lifetime episodes of syncope and
with a tilt-table test that induced syncope or presyncope, as well as
a relative bradycardia, were randomized to receive a dual-
chamber pacemaker or not. The pacemaker prevented bradycar-
dia and provided high-rate pacing if a predetermined drop in
heart rate occurred (rate-drop response). The primary outcome
was the first recurrence of syncope. Patients also completed a
detailed diary recording presyncopal episodes.
Results. A total of 284 patients was originally planned and a
pilot study of 60 patients was initiated. At the planned first formal
interim analysis of efficacy of the pilot study, an unanticipated
large treatment effect was observed which fulfilled the prespecified
criteria for early termination of the study. At that time, there were
54 patients enrolled, randomized evenly to no pacemaker or to
pacemaker. In the no-pacemaker and pacemaker groups the mean
ages were 40 and 46 years; 74% and 70% patients, respectively,
were female. The baseline tilt-table test showed a slowest heart
<60/min or longest heart period >1000 ms in 60% of no-
pacemaker patients and 72% of pacemaker patients. There was a
marked reduction in the postrandomization risk of syncope in
pacemaker patients (relative risk reduction 85.4%, 95% confi-
dence interval 59.7% to 94.7%; 2p 5 0.000022).
Conclusions. Dual-chamber pacing with rate-drop response
reduces the likelihood of syncope in patients with recurrent
vasovagal syncope.
(J Am Coll Cardiol 1999;33:16–20)
©1998 by the American College of Cardiology
Vasovagal or neurally mediated syncope is a common condi-
tion caused by inappropriate reflex vasodilation and bradycar-
dia. Recently, the increased use of tilt-table testing to elicit
vasovagal syncope has confirmed a high prevalence of relative
bradycardia at the time of fainting and has heightened interest
in the use of pacemaker therapy (1–8). The usefulness of
See page 21
cardiac pacing has, however, been questioned owing to the
observation that vasodilation usually accompanies bradycardia at
the time of fainting. Several observational nonrandomized studies
(6–8) have suggested a possible benefit from pacing but no
randomized controlled trial has been done. The goal of this study
(9) was to perform a randomized controlled trial of pacemaker
therapy in vasovagal syncope. The pacemaker used for this study
not only provided bradycardia support by dual-chamber pacing
but also had rate-drop responsiveness. With this feature, the
pacemaker can be programmed to detect a small, rapid drop of
heart rate through a prespecified range, then pace at a relatively
high rate to provide chronotropic support during a time of
presumed vasodilation. The primary hypothesis was that a deci-
sion to implant a pacemaker would reduce the risk of syncope
compared to not implanting a pacemaker.
Methods
Patient eligibility. The study protocol was published previ-
ously (9). Patients were eligible for inclusion if they had had at
least six syncopal spells in order to provide a probability of a
recurrence of $50% in 1 year (10). Patients also had to have
had a positive tilt-table test with syncope or presyncope and
with relative bradycardia. Relative bradycardia was defined as
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a trough heart rate ,60/min if no isoproterenol was used,
,70/min if up to 2 mcg/min isoproterenol was used, or
,80/min if over 2 mcg/min isoproterenol was used. Each
participating clinical center used its own tilt-table test protocol.
Patients were excluded if they had other causes of loss of
consciousness such as ventricular tachycardia, complete heart
block, postural hypotension, hypersensitive carotid sinus syn-
drome or seizures. They were excluded if they had important
valvular, coronary, myocardial or conduction abnormality; or if
they had previous pacemaker therapy, a contraindication to
insertion of a permanent pacemaker, or a major chronic
noncardiovascular disease.
Definitions. Syncope was defined as a transient state of
unconsciousness characterized by spontaneous recovery. Pre-
syncope was defined as a state of lightheadedness usually
associated with one or more symptoms of decreased vision, the
sensation of hearing voices distantly, slow response times to
verbal stimuli, nausea, vomiting, or partial loss of postural tone.
Randomization and follow-up. Patients were randomized
centrally by telephone either to receive a permanent pace-
maker or not. Patients randomized to receive a pacemaker did
so at the earliest possible date, and the protocol specified that
the pacemaker be implanted within a week of randomization.
The pacemaker used was the Medtronic Thera DR dual-
chamber pacemaker with rate-drop response. The rate-drop
response algorithm and pacing parameters were activated
within 24 h of implant and prior to the patient leaving hospital.
A minimum pacing rate of 60 beats/min was programmed in all
patients. The initial rate-drop response parameters were pro-
grammed to detect a “rate drop” if there was a fall in heart rate
of 5 to 15 beats/min over a sequence of 20 to 40 beats that
remained below the lower rate for at least three beats. If this
occurred, a pacing response of 100 beats/min for 2 min would
occur. Patients in both groups were permitted to receive any
medical or nonmedical treatment, according to the judgment
of their treating physicians, but none was required. Following
discharge, patients completed a daily diary of all presyncopal
and syncopal spells. In addition, the patients were either
contacted by telephone or seen every 2 months by study nurses.
Study design. The goal of the study was to test the hypoth-
esis that the decision to implant a dual-chamber pacemaker
with rate-drop response would reduce the risk of a first
recurrence of syncope compared to no pacemaker. We elected
not to implant a pacemaker in control patients (which would
not be activated) because, in 1995 when the trial was designed,
the evidence in support of pacing was sufficiently scant that we
wanted to minimize the number of patients who received this
invasive therapy.
Outcome measures. The primary outcome measure of the
study was the first recurrence of syncope. This was chosen
because the time to the first recurrence of syncope has been
shown to correlate very well with the eventual frequency of
syncope (11), and the frequency of syncope in turn correlates
with the diminution of quality of life in patients with frequent
vasovagal syncope (12). Once a patient had a recurrence of
syncope, formal study participation ended.
The verification of syncope was done by careful documen-
tation of the features of the syncopal spell as reported by the
patient, by obtaining collateral history from bystander wit-
nesses, and by examination of the patient for signs of physical
trauma such as abrasions or contusions. All patients were given
diaries to record their symptoms of presyncope and syncope,
and were instructed to grade their presyncopal symptoms daily
on a 10-point scale, ranging from 0 (no symptoms) to 10
(syncope). Patients were interviewed in the clinic or by tele-
phone within 1 week of any syncopal spell. Each investigator
decided whether an outcome event had occurred based upon
whether complete loss of consciousness had happened, and
whether the loss of consciousness was similar to previous
vasovagal syncope.
Statistical methods. Because patients were followed for
varying lengths of time and the primary outcome event,
recurrence of syncope, could occur at any time postrandom-
ization, survival analysis techniques were used. The cumulative
risk of syncope over time was estimated within each treatment
group using the Kaplan-Meier procedure (13), and the two
survival curves were formally compared using a Mantel-
Haenszel test (14). The treatment effect and its associated 95%
confidence interval were represented by a relative risk reduction
and computed with a Cox proportional hazards model (15). The
Cox model was also used to adjust for baseline imbalances in a
predetermined set of potentially important prognostic factors and
to investigate possible subgroup interactions.
Because we anticipated a 1-week delay in pacemaker im-
plantation for those patients allocated to receive a pacemaker,
the protocol specified that, for the primary analysis of efficacy,
no outcome events would be counted until the eighth postran-
domization day. All analyses were based on the intention-to-
treat principle.
The assumptions for the sample size calculation were that
the no-pacemaker group would have a cumulative risk of
recurrent syncope at 1 year of 60%. We calculated that a total
of 286 patients would yield 80% power to detect a 30% relative
reduction in risk of recurrent syncope (based on a one-sided
type I error of 5%).
A pilot study of 60 patients was initiated in June 1995.
Formal interim analysis of efficacy was specified in the protocol
(9) for both the pilot and main studies with early study
termination for p , 0.001. The study was approved by the
Institutional Review Boards of all participating sites.
Results
Early termination for efficacy. The study began to enroll
patients in June 1995 and the first formal interim analysis of
efficacy was carried out on April 30, 1997. Although 54 patients
had been enrolled at that time, follow-up data for interim
analysis were available from 46 patients in whom a treatment
effect in favor of pacing was observed (p 5 0.0007). In consulta-
tion with the External Safety and Efficacy Monitor, a decision was
made to terminate enrollment and follow-up, and to report the
study results as of May 2, 1997. An unknown number of patients
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were screened and found to be eligible for the study; of the 54
who gave consent and were enrolled, 27 were assigned to receive
no pacemaker and 27 were assigned to receive a pacemaker.
Baseline characteristics. Table 1 shows the clinical charac-
teristics of the two groups. The mean age of patients was 43
years, and almost three-quarters were female. There was a low
incidence of diabetes mellitus, systemic hypertension and lung
disease. Patients had a heavy burden of prior syncope, with
median lifetime history of 35 episodes (no pacemaker) and 14
episodes (pacemaker). The median number of episodes in the
year preceding enrollment was 6 (no pacemaker) and 3
(pacemaker). The mean time between the most recent episode
of syncope and randomization was 63 days (no pacemaker) and
92 days (pacemaker). Beta-blocker therapy had been used
unsuccessfully in 40% of patients and disopyramide in 11%.
All patients had a positive tilt-table test; with both syncope/
presyncope and bradycardia. Syncope was induced in 63% of
no-pacemaker patients and 77% of pacemaker patients. Fewer
than one-third of patients developed a heart rate ,40/min or
longest heart period .1500 milliseconds (ms) during the tilt test.
Pacemaker therapy. A pacemaker was implanted in 26 of
27 patients randomized to the pacemaker group; one patient
refused. None of the patients randomized to no-pacemaker
received a pacemaker prior to experiencing an episode of
recurrent syncope (which ended formal study participation).
The mean time from randomization to pacemaker implanta-
tion was 6.7 days with a range of 1 to 22 days. Eighteen patients
(69%) allocated to receive a pacemaker had it implanted
within 7 days of randomization. All patients were initially
programmed into the dual-chamber pacing mode with a min-
imum rate of 60/min, with the rate-drop response function
programmed on. One patient was subsequently programmed
to rate responsive dual-chamber pacing with the rate-drop
response programmed off.
Recurrent syncope. The protocol specified that events
would only be included in the primary analysis if they occurred
at least 7 days after randomization to allow time for pacemaker
implantation. Figure 1 shows the cumulative rate of recurrent
syncope (excluding the first 7 days after randomization) in the
no-pacemaker and pacemaker groups. There was a reduction
in risk of syncope of 85.4% (relative risk reduction 85.4%, 95%
confidence interval, 59.7% to 94.7%; 2p 5 0.000022). Recur-
rent syncope occurred in 19/27 (70%) of no-pacemaker pa-
tients and in 6/27 (22%) of pacemaker patients. The mean time
from randomization to syncope was 54 days in the no-
pacemaker group and 112 days in the pacemaker group. The
syncope episode was witnessed in 6 of the 19 no pacemaker
patients and in 3 of the 6 pacemaker patients. There was
evidence of injury in 4 of the no-pacemaker patients with
syncope (bruises) and none of the pacemaker patients with
syncope. During follow-up, 2/27 (7%) of patients in both
treatment groups received a beta-blocking drug; disopyramide
was used by one patient in the no-pacemaker group. No other
drugs were prescribed for the treatment of syncope or presyn-
cope. During the first 7 days after randomization, six patients
in the no-pacemaker group and none in the pacemaker group
had syncope.
Presyncope. All patients were instructed to maintain a
daily diary of presyncope episodes that was reviewed by the
study nurse. As shown in Table 2, there was no significant
effect of pacing on the occurrence of presyncope. At least one
episode of presyncope was reported by 20 (74%) no-
pacemaker patients and 17 (63%) pacemaker patients. Epi-
sodes of presyncope were rated by patients on a numeric scale
Table 1. Baseline Clinical Characteristics
Feature
No-Pacemaker
Group
Pacemaker
Group
No. of patients 27 27
Mean age 6 SD 40 6 18 46 6 18
Female (%)20 (74) 19 (70)
Non–insulin-dependent
diabetes (%)
2 (7) 0
Hypertension on therapy (%) 3 (11) 4 (15)
Chronic lung disease (%) 1 (4) 2 (7)
Syncope episodes lifetime,
median (IQR)
35 (20–100) 14 (8–35)
Syncope episodes last year,
median (IQR)
6 (3–40) 3 (2–12)
Mean days from most recent
syncope episode to
randomization (6SD)
63 6 130 92 6 126
Prior therapy for syncope
Beta-blocker (%) 11 (41) 12 (44)
Disopyramide (%) 3 (11) 3 (11)
Fludrocortisone (%) 1 (4) 2 (7)
Baseline tilt-table test
Isoproterenol used (%) 18 (67) 21 (78)
Syncope induced (%) 17 (63) 20 (74)
Lowest heart rate ,60/min
or longest RR .1000 ms
17 (63) 20 (74)
Lowest heart rate ,40/min
or longest RR .1500 ms
7 (26) 5 (19)
IQR 5 interquartile range; SD 5 standard deviation.
Figure 1. Kaplan-Meier plots of the time to the first recurrence of
syncope among 27 patients randomized to receive a pacemaker and 27
patients randomized to not receive a pacemaker by intention-to-treat
analysis.
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(1 to 10, in increasing severity). At least one presyncope event
of severity $8 was reported by 48% of no-pacemaker patients
and by 37% of pacemaker patients. A rate of presyncope of
.10 episodes/100 days was reported by 36% of no-pacemaker
and by 22% of pacemaker patients. The average rates of
presyncope episodes per 100 days were 10.0 for no-pacemaker
patients and 4.5 for pacemaker patients.
Adjusted analysis and subgroup effects. With a relatively
small study, there is scope for baseline imbalances in poten-
tially important prognostic factors to occur, despite random-
ization. There was a trend for no-pacemaker patients to have
had more syncopal episodes in the year preceding randomiza-
tion than pacemaker patients. To determine if any baseline
characteristics were predictive of recurrent syncope and to
determine if observed baseline imbalances might have had an
impact on the relative risk reduction, an adjusted analysis was
performed. The baseline factors considered were age (,40
years, $40 years), number of syncopal events in the past year
(,4, $4), lifetime syncopal events (,20, $20), days since most
recent syncope (#37, .37), tilt-test minimum heart rate of
,40 beats/min or maximum heart period .1500 ms (yes/no),
tilt-test syncope (yes/no) and tilt-test seizure-like activity (yes/
no). When included together in a Cox model, none of these
variables were significantly predictive of recurrent syncope.
Therefore, when the estimate of pacemaker efficacy was ad-
justed for the observed differences between the groups in these
baseline factors, the estimated treatment effect was unchanged
(relative risk ratio 5 90.8%, 95% confidence interval 71.0% to
97.1%, 2p 5 0.000045). Thus, it is highly unlikely that baseline
differences between the patient groups explains any of the
observed effect on syncope.
To explore the possibility that the pacemaker treatment
effect varied in the presence or absence of any of these baseline
characteristics, treatment–covariate interactions were evaluated
in the Cox model. None of these interactions were statistically
significant, even without allowance for multiple testing.
Adverse effects. Seven adverse events were reported for the
pacemaker patients and none for the no-pacemaker patients.
There was one pacemaker lead dislodgement. Five patients
reported at least one episode of palpitations, and one patient
reported pacemaker activity at rest.
Discussion
This was the first randomized controlled trial of pacemaker
therapy in vasovagal syncope. It demonstrated that in patients
who are severely symptomatic from vasovagal syncope, perma-
nent pacing markedly reduces the likelihood of a recurrence of
syncope. In contrast, pacing has little effect on the occurrence
of presyncope, which was common in these patients.
Mechanism of action. The pacemaker could have benefited
these patients in at least two ways. By providing a minimum
heart rate of 60 beats/min, the pacemaker prevented extreme
bradycardia and asystole, which has been observed to occur
with vasovagal syncope in many patients. A second mechanism
of potential benefit was the rate-drop response feature, which
automatically provided high rate (usually 100 to 120 beats/min)
dual-chamber pacing if an abrupt drop in heart rate was
detected. This intervention might prevent an episode of vaso-
vagal syncope by augmenting cardiac output at the initiation of
a vasovagal episode. This study was not designed to determine
the mechanism of pacemaker effectiveness. Prevention of
bradycardia, rate-drop response, both interventions or other
mechanisms of benefit may be responsible for the observed
effect.
This study design cannot exclude a bias in assessment of
outcome as the treatment was unblinded. There was, however,
objective verification of many syncope episodes. Of the 25
syncope episodes that were reported by patients and deter-
mined to be outcome events, 36% were witnessed and 16%
were associated with documented minor injury. As the study
was unblinded and patients knew whether they were receiving
the experimental therapy or not, there is some potential for a
placebo-type effect or psychological benefit from receiving a
pacemaker. An imbalance in events reported during the first
week after randomization when some pacemaker patients had
not yet received a device suggests that some psychological
effect may have occurred. Conversely, if the large reduction in
syncope that was observed was due to a placebo or psycholog-
ical mechanism, one would have expected this to carry over
into the area of presyncope, yet there was no significant effect
of pacing on presyncope.
A reduction in syncope without effect on presyncope actu-
ally corresponds closely with the known pathophysiology of
vasovagal syncope, which includes both bradycardia and vaso-
dilation. Pacing will prevent bradycardia but is unlikely to
prevent vasodilatation. Thus, a patient with a pacemaker
experiencing a vasovagal episode might well be expected to
continue to have vasodilatation, which would explain the
persistence of presyncope. The observation that pacemaker
therapy has an effect on syncope but not on presyncope has
been previously reported by Sra et al. (2) in a study of 22
vasovagal syncope patients undergoing tilt-table testing before
and after pacemaker therapy. In that study, 18 patients had
syncope before pacing and only 5 after pacing; however,
presyncope persisted in all but one patient.
Adjusted analysis. Despite randomization, there was a
trend for pacemaker patients to have had fewer lifetime
Table 2. Presyncope Characteristics
Outcome
No-Pacemaker
Group
Pacemaker
Group Significance
Number of patients with
presyncope in follow-up
20/27 (74%) 17/27 (63%) 0.56
Average rate of
presyncope, episodes/
100 days
10.0 4.5 0.21
Number of patients with
frequency of presyncope
episodes .10/100 days
9/25* (36%) 6/27 (22%) 0.36
Number of patients with
any severe presyncope
($8 on 1–10 scale)
12/25* (48%) 10/27 (37%) 0.58
*Data not available on two patients.
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episodes of syncope and fewer episodes in the past year.
Although one might be concerned that a chance baseline
imbalance might have exaggerated the treatment effect, this
appears unlikely. Syncope burden prior to randomization was
not a predictor of recurrent syncope, and when the relative risk
reduction is adjusted for differences in baseline variables, it
remains essentially unchanged.
One might argue that the time to recurrence of syncope is
less important then the total burden of syncope. We have,
however, previously shown that the time to first recurrence of
syncope is closely correlated with total syncope episodes in the
year following diagnostic tilt-table testing of vasovagal syncope
(11). Furthermore, there was a practical reason to choose first
recurrence of syncope as the primary outcome measure. We
expected that patients not receiving a pacemaker would be
unwilling to persist in the study after they had experienced a
recurrence.
Unanswered questions. There are several remaining ques-
tions not addressed by this study. It is not known to what extent
the rate-drop response function is required to obtain a benefit
from pacemaker therapy. A randomized comparison of dual-
chamber pacing with and without rate-drop intervention would
be useful. The patients enrolled in this study were highly
selected. They had a substantial burden of previous syncope
and they had relative bradycardia demonstrated on a tilt-table
test. It is unknown to what extent other patients with vasovagal
syncope would benefit from pacing, especially those with less
frequent syncope or those without bradycardia or symptoms at
the time of tilt-table testing. We did not determine whether
pacemaker therapy improved the quality of life in patients with
vasovagal syncope in this study. However, in a recent two-
period study we have shown that quality of life improved
markedly and significantly in patients with vasovagal syncope
who received a dual-chamber pacemaker (8).
Patients with recurrent vasovagal syncope can be severely
disabled. They may seriously injure themselves on occasion
and they may not be able to drive a car or to perform their jobs.
Beta-blocking drugs, disopyramide and fludrocortisone have
been used to treat vasovagal syncope but none have been
demonstrated in randomized trials to prevent syncope. The
findings of this study provide strong evidence that pacemaker
therapy can help some patients with vasovagal syncope.
A study in which all patients receive a pacemaker with
subsequent blinded randomization to pacemaker on or pace-
maker off would provide even stronger evidence that pace-
maker therapy helps these patients. At present a reasonable
management strategy for patients with highly frequent and
symptomatic vasovagal syncope would be to provide counsel-
ing about lifestyle modification and increased dietary salt; then
to discuss with the patient whether to try empiric pharmaco-
logical therapy. It would then be reasonable to consider
implanting a pacemaker in patients with highly symptomatic,
frequent vasovagal syncope who also have a relative bradycar-
dia on tilt-table testing.
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Members of the Vasovagal Pacemaker
Study Investigators
Clinical Sites and Investigators: University of Calgary, Calgary: Robert
Sheldon, Mary Lou Koshman; McMaster University, Hamilton: Stuart Connolly,
Mariane Menard; Cleveland Clinic Foundation, Cleveland: Fred Jaeger, Bruce
Wilkoff, Fetnat Fouad, Donald Holmes; Institut de Cardiologie de Montreal,
Montreal: Mario Talajic, Denis Roy, Danielle Beaudoin; St. Michael’s Hospital,
Toronto: David Newman, Miney Paquette, Paul Dorian, Jane Laslop; Hospital du
Sacre-Coeur, Montreal: T. Kus, Ginette Gaudette; University Hospital, Kingston:
H. Abdollah; Medical College of Virginia Hospital, Richmond: Kenneth Ellenbo-
gen, Carlos Morillo, Cheryl Dietrich; University of Ottawa Heart Institute, Ottawa:
Martin Green, Anthony S. L. Tang, Clare Carey; University Hospital, London:
Raymond Yee, George Klein, Marilyn Braney; Laval Hospital, Saint-Foy:
Francois Philipon, Marcel Gilbert, Gilles O’Hara, Johanne Rompre; Temple
University School of Medicine, Philadelphia: Alfred Buxton, Henry Hsia, Nancy
Adelizzi; Lansing, Michigan: Rajan Thakur, Terry Mangum; Sacramento, Cali-
fornia: Gearoid O’Neill, Arjun Sharma, Anne Skadsen; Canton, Ohio: Raquel
Martin, James Maloney, Ladyne Miller; Bowman Gray Medical Centre, Winston-
Salem, North Carolina: George H. Crossley, Kathleen Davis-O’Brien.
Coordinating and Methods Centre, Hamilton, Ontario: Michael Gent,
Robin Roberts, Natasha LaPierre.
External Safety and Efficacy Monitor: D. George Wyse.
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